Patent litigation attorney
Michelle E. Irwin
2 tracked appearances — 0 plaintiff · 2 defendant.
Specialty & background
Attorney Summary: Michelle E. Irwin (Fenwick & West LLP)
Focus areas. Irwin's practice centers on life sciences patent litigation, per her Fenwick profile: biologics and small-molecule pharmaceutical disputes, Hatch-Waxman/ANDA litigation, and traditional infringement actions involving formulation, drug-product, and method-of-treatment claims. She also advises on patent strategy, IP portfolio evaluation, and related regulatory matters. Her tracked litigation appearances, however, are outside pharma — most prominently the Flexiworld Technologies wireless-printing/software dispute — which is consistent with a Seattle-based associate serving in a local-counsel capacity for a broader Fenwick team, rather than a separate technology focus of her own.
Side preference. Both of her tracked appearances are on the defense side (0 plaintiff / 2 defendant), and both are identified as local counsel. Firm-published work confirms this defense orientation: she is listed on Fenwick's team defending ANDA filers in the In re Ozempic (Semaglutide) Patent Litigation MDL (D. Del.) and on the Fenwick team that obtained a favorable pretrial and eve-of-trial settlement for client Avalyn Pharma against a former shareholder's patent-rights claims. No plaintiff-side or NPE/PAE representation appears in the tracked record.
Firm context. Irwin is currently at Fenwick & West LLP, based in its Seattle office, where she is an associate/litigator. Her Fenwick bio states that before joining the firm she was an associate at an Am Law 50 firm focused on pharmaceutical, biotech, and chemical patent litigation (the prior firm is not named in the source). No in-house role is indicated.
Notable cases. (1) Flexiworld Technologies, Inc. v. Amazon.com Inc. et al., No. 2:21-cv-01055 (W.D. Wash.) — Flexiworld's wireless-print patent suit against Amazon entities; Irwin appears as local counsel. The court issued a claim-construction order in March 2024, and the case was terminated in July 2025. I found no reported verdict, Federal Circuit appeal, or publicly verified settlement amount. (2) The second tracked matter is unlabeled in the source data, so I cannot describe it. (3) In re Ozempic (Semaglutide) Patent Litigation, MDL No. 22-3038 (D. Del.) — Irwin appears in service/discovery correspondence for the Fenwick team defending ANDA defendants against Novo Nordisk; no outcome attributable to her is verifiable. (4) Avalyn Pharma favorable resolution — named in Fenwick's published team list; the firm reports summary judgment on one claim and an insignificant-amount settlement.
PTAB / IPR experience. I found no evidence that Irwin personally appears in IPR/PGR proceedings before the PTAB. Related Flexiworld IPRs are handled by other Fenwick counsel and by Flexiworld's own counsel; I would not attribute those proceedings to her without further verification.
Bar / education. J.D., The George Washington University (2015); admitted to the Washington State Bar (2022). Recognized in Best Lawyers: Ones to Watch (Litigation–Patent) since 2023. Other bar admissions, if any, are not confirmed by the sources reviewed.
Firms
Roles
- local counsel2
Cases (2)
- Δ defendantFlexiworld Technologies, Inc. — Case 6:20-cv-00553Fenwick & West · local counsel
- Δ defendantFlexiworld Technologies, Inc. v. Amazon.com Inc. et al.Fenwick & West · local counsel